V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016388 | 160018109 | null | 17.1 | Palliative (P) | 2018-05-01 | 2018-05-03 | CISPLATIN + ETOPOSIDE | 02 | N | NOT MATCHED | 101042391 |
| 160016389 | 160018110 | 1.82 | null | null | 2017-05-05 | 2017-05-13 | DACARBAZINE + GEMCITABINE | 02 | null | LAROTRECTINIB | 100501408 |
| 160016409 | 160018111 | 1.9 | 44.8 | Curative (C) | 2019-04-29 | 2019-04-29 | ETOP 13-18 BEAT-meso Trial | 01 | N | OLAPARIB | 101579720 |
| 160016428 | 160018112 | 1.8 | 16.8 | null | 2020-01-09 | 2020-01-12 | Etoposide + Ifosfamide (3 days) | 02 | null | EW EUROEWING 2012 ARM B VC | 101731054 |
| 160016429 | 160018113 | null | 93.1 | null | 2017-06-06 | 2017-06-13 | NEMO TRIAL | 02 | null | IFOSFAMIDE | 100736808 |
| 160016444 | 160018115 | 1.64 | 68 | null | 2020-03-16 | 2020-03-30 | Ifosfamide 3g/m2 5 day | 2 | null | DOXORUBICIN + IFOSFAMIDE | 100920605 |
| 160016447 | 160018116 | 1.68 | 0 | Curative (C) | 2019-04-13 | 2019-04-21 | Doxorubicin + Ifosfamide | Y | Y | STS RHABDO RMS 2005 VIN CYCLO | 101003237 |
| 160016462 | 160018117 | 1.85 | 74 | Neo-adjuvant (N) | null | 2017-05-06 | EW EuroEwing 2012 Arm B IE | 02 | N | NOT MATCHED | 101660087 |
| 160016467 | 160018118 | 1.55 | 17.5 | Palliative (P) | null | 2018-08-02 | EW EuroEwing 2012 Arm B IE | null | null | IRINOTECAN + TEMOZOLOMIDE | 100434212 |
| 160016468 | 160018119 | 0.98 | 60.5 | Palliative (P) | 2018-03-05 | 2018-04-02 | NB HRNBL-1 COJEC Ind COURSE C | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101166820 |
| 160016477 | 160018120 | 1.63 | 63.9 | null | 2018-06-20 | 2019-08-18 | Irinotecan + Temozolomide | 02 | null | OLAPARIB | 101786150 |
| 160016479 | 160018121 | 1.6 | 86 | null | 2019-08-01 | 2019-08-06 | Olaratumab | Y | null | GEMCITABINE | 100294636 |
| 160016488 | 160018122 | 1.71 | 74.7 | 02 | 2018-06-09 | 2018-06-24 | EW EuroEwing 2012 Arm B IE | 02 | N | EW EUROEWING 99 : VACTI | 100949605 |
| 160016489 | 160018123 | 1.66 | 108 | Adjuvant (A) | 2017-06-10 | 2017-07-19 | NEMO TRIAL | null | null | RMS 2005 TRIAL | 100100749 |
| 160016492 | 160018124 | 1.7 | 78.2 | null | null | null | Irinotecan + Temozolomide | 02 | null | DOCETAXEL | 101692118 |
| 160016496 | 160018125 | null | 52 | Palliative (P) | 2018-04-01 | 2018-04-17 | NB Rel CCLG guidelines Cyclo-Topotecan | 02 | null | TRAMETINIB | 100199683 |
| 160016503 | 160018126 | 1.76 | 118 | 03 | 2017-03-09 | 2017-03-22 | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | N | N | GEMCITABINE | 101759217 |
| 160016516 | 160018127 | 1.89 | 57.6 | null | 2017-02-13 | 2017-03-09 | MELPHALAN + THALIDOMIDE | null | null | EW EUROEWING 2012 ARM B VDC/IE | 100085188 |
| 160016526 | 160018128 | 0 | 91.8 | Neo-adjuvant (N) | null | null | Bendamustine+Rituximab(Sub Courses) | 01 | N | VINCRISTINE | 101319145 |
| 160016530 | 160018130 | 1.64 | 77.9 | null | 2018-01-11 | 2018-07-13 | Etoposide oral | 02 | null | ETOP 13-18 BEAT-MESO TRIAL | 101066328 |
| 160016540 | 160018131 | 0 | 71.35 | null | 2021-04-21 | 2021-04-28 | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | null | OLAPARIB | 101003034 |
| 160016547 | 160018132 | 0 | 81 | Adjuvant (A) | 2018-09-16 | 2018-10-10 | Etoposide oral | 02 | Y | NOT MATCHED | 100387025 |
| 160016557 | 160018133 | 1.53 | 65 | null | 2020-05-17 | 2020-05-30 | STS Rhabdomyosarcoma RMS 2005 IVA | N | null | BEVACIZUMAB + CISPLATIN + PEMETREXED | 100069644 |
| 160016564 | 160018134 | 1.71 | null | null | null | 2020-01-31 | DACARBAZINE + GEMCITABINE | 02 | null | LANREOTIDE | 100599975 |
| 160016568 | 160018135 | 1.64 | 141.6 | null | 2019-03-14 | 2019-03-30 | null | 02 | null | CONFIRM TRIAL | 100064632 |
| 160016570 | 160018136 | 1.63 | 74.9 | Curative (C) | 2017-02-13 | 2017-03-03 | CONFIRM TRIAL | 01 | N | CARBOPLATIN + ETOPOSIDE | 100711765 |
| 160016573 | 160018137 | 1.14 | 12.5 | null | 2019-12-10 | 2020-01-19 | Olaparib | 02 | null | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100506796 |
| 160016576 | 160018138 | 0 | null | Curative (C) | 2021-01-08 | 2021-02-11 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | LENALIDOMIDE | 101269451 |
| 160016581 | 160018139 | 1.6 | 79 | Palliative (P) | 2019-11-25 | 2019-12-02 | VAC | 02 | N | NOT MATCHED | 101110125 |
| 160016583 | 160018140 | 0 | 20.7 | null | 2018-12-30 | 2020-07-27 | NB HRNBL-1 COJEC Ind COURSE C | 02 | null | EW EUROEWING 2012 ARM A VAC | 101370304 |
| 160016584 | 160018141 | 0 | 89.8 | 02 | 2020-05-11 | 2020-05-29 | STS Non-Rhabdo EpSSG 2005 Vcy | 02 | N | OLARATUMAB | 100622382 |
| 160016587 | 160018142 | 1.55 | 7.9 | Palliative (P) | 2021-04-22 | 2022-01-26 | EW Rel Irinotecan & Temozolomide | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 101439690 |
| 160016589 | 160018143 | 1.67 | 71.4 | null | 2022-02-22 | 2022-03-08 | Doxorubicin + Ifosfamide | 02 | null | IFOSFAMIDE | 100705812 |
| 160016596 | 160018144 | 0 | 95.3 | Palliative (P) | 2020-02-22 | 2020-02-22 | Cyclophosphamide + Topotecan | 02 | N | ETOPOSIDE | 101238130 |
| 160016600 | 160018145 | 1.8 | 59.9 | Neo-adjuvant (N) | 2019-12-07 | 2020-03-28 | NB HRNBL-1 COJEC Ind COURSE B | 02 | N | EW REL REECUR IRINOTECAN/TEMOZOLOMIDE | 100627325 |
| 160016601 | 160018146 | 1.56 | 81.9 | null | 2017-03-27 | 2017-09-09 | Cyclophosphamide Weekly PO | 01 | null | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 101288706 |
| 160016613 | 160018147 | 1.62 | 40 | Palliative (P) | 2017-03-04 | 2017-08-07 | STS Rhabdo RMS 2005 Vin Cyclo | N | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101487963 |
| 160016631 | 160018148 | 1.63 | 11.8 | null | 2019-01-29 | 2019-02-18 | DACARBAZINE + DOXORUBICIN | 02 | null | NB HRNBL-1 BUMEL MAT | 100602223 |
| 160016634 | 160018149 | 1.64 | 71 | null | 2018-09-12 | 2018-09-12 | Doxorubicin + Ifosfamide | 02 | null | DACARBAZINE + GEMCITABINE | 101340491 |
| 160016636 | 160018150 | 1.64 | 66.8 | Curative (C) | 2020-07-13 | 2021-01-10 | EW EuroEwing 2012 Arm B IE | 02 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100921383 |
| 160016640 | 160018151 | 1.81 | 73.8 | Palliative (P) | 2018-08-03 | 2018-11-02 | Hydroxycarbamide | 02 | N | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 100225927 |
| 160016641 | 160018152 | 1.58 | 83.5 | Palliative (P) | 2017-06-07 | 2017-06-08 | EW EuroEwing 2012 Arm A VAC | N | N | DOXORUBICIN + IFOSFAMIDE | 100119618 |
| 160016655 | 160018153 | 1.83 | 72.5 | null | null | 2019-12-04 | FLUOROURACIL + IRINOTECAN | 02 | null | BLEOMYCIN | 100203446 |
| 160016660 | 160018154 | null | 54.2 | Palliative (P) | 2022-05-20 | 2022-05-20 | Gemcitabine day 1&8 | N | null | IPILIMUMAB + NIVOLUMAB | 101339215 |
| 160016666 | 160018156 | null | 39 | Palliative (P) | 2020-02-08 | 2020-02-08 | NB Rel CCLG guidelines Irin & Temoz | 02 | N | IFOSFAMIDE | 101163761 |
| 160016669 | 160018157 | 1.59 | 69.7 | Palliative (P) | 2020-08-08 | 2020-08-08 | Trial Unspecified | 02 | N | NIRAPARIB | 101742044 |
| 160016671 | 160018158 | 0 | 16.4 | Palliative (P) | 2020-11-10 | 2020-11-10 | Pemetrexed | 02 | N | NEMO TRIAL | 100844767 |
| 160016675 | 160018159 | 1.3 | 70.6 | Neo-adjuvant (N) | 2020-05-31 | 2020-08-03 | CARBOPLATIN + ETOPOSIDE | 02 | null | TRASTUZUMAB | 100872158 |
| 160016686 | 160018160 | null | 65.5 | null | 2016-12-05 | 2017-07-23 | NB BEACON Dinutuximab, Cyclophosphamide and Topotecan | 02 | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 100022000 |
| 160016692 | 160018161 | 1.79 | 77.3 | Palliative (P) | 2020-10-12 | 2020-10-12 | null | 02 | null | NB LOW/INTERM RISK GUIDELINES CARBO/ETOP | 100161840 |